Search by Drug Name or NDC

    NDC 61958-1004-01 Ranexa 1000 mg/1 Details

    Ranexa 1000 mg/1

    Ranexa is a ORAL TABLET, FILM COATED, EXTENDED RELEASE in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Gilead Sciences, Inc.. The primary component is RANOLAZINE.

    Product Information

    NDC 61958-1004
    Product ID 61958-1004_3c62f26b-5dfd-40cf-bc8c-43a9124577e2
    Associated GPIs 32200040007430
    GCN Sequence Number 062973
    GCN Sequence Number Description ranolazine TAB ER 12H 1000 MG ORAL
    HIC3 A2C
    HIC3 Description ANTIANGINAL, ANTI-ISCHEMIC AGENTS,NON-HEMODYNAMIC
    GCN 98733
    HICL Sequence Number 033446
    HICL Sequence Number Description RANOLAZINE
    Brand/Generic Brand
    Proprietary Name Ranexa
    Proprietary Name Suffix n/a
    Non-Proprietary Name RANOLAZINE
    Product Type HUMAN PRESCRIPTION DRUG
    Dosage Form TABLET, FILM COATED, EXTENDED RELEASE
    Route ORAL
    Active Ingredient Strength 1000
    Active Ingredient Units mg/1
    Substance Name RANOLAZINE
    Labeler Name Gilead Sciences, Inc.
    Pharmaceutical Class Anti-anginal [EPC], Cytochrome P450 2D6 Inhibitors [MoA], Cytochrome P450 3A Inhibitors [MoA], Organic Cation Transporter 2 Inhibitors [MoA], P-Glycoprotein Inhibitors [MoA]
    DEA Schedule n/a
    Marketing Category NDA
    Application Number NDA021526
    Listing Certified Through n/a

    Package

    NDC 61958-1004-01 (61958100401)

    NDC Package Code 61958-1004-1
    Billing NDC 61958100401
    Package 60 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE, PLASTIC (61958-1004-1)
    Marketing Start Date 2007-02-12
    NDC Exclude Flag N
    Pricing Information
    Price Per Unit 10.7141
    Pricing Unit EA
    Effective Date 2021-01-01
    NDC Description RANEXA ER 1,000 MG TABLET
    Pharmacy Type Indicator C/I
    OTC N
    Explanation Code 4
    Classification for Rate Setting B
    As of Date 2022-01-12
    This pricing file, entitled the NADAC (National Average Drug Acquisition Cost) files, provide state Medicaid agencies with covered outpatient drug prices by averaging survey invoice prices from retail community pharmacies across the United States. These pharmacies include independent retail community pharmacies and chain pharmacies. The prices are updated on a weekly and monthly basis